CE Marking for Momentum Biosciences’ Innovative Blood Culture Test
Momentum Bioscience Ltd is pleased to announce that it has CE marked Cognitor® Minus, the first in a range of products for the hospital microbiology laboratory utilising ETGA®. ETGA® is a novel technology for the rapid, universal detection of viable bacteria & fungi.
Cognitor® products are designed for the rapid detection/exclusion of infection, assisting clinicians with antibiotic stewardship, improved patient outcomes and treatment costs.
Patients at risk of sepsis are routinely placed on broad-spectrum intravenous antibiotics until definitive information is available from blood culture samples sent to the hospital laboratory. Up to 90% of blood cultures are negative but take 5 days to be confirmed as such. Cognitor® Minus gives a confirmed negative result, direct from blood culture, the day following sample receipt by the laboratory with a negative predictive value (NPV) of 99.5%.
Cognitor® Minus will have its formal launch at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Copenhagen, Denmark on 25th - 28th April 2015.
Note: This product is currently not available for sale in the USA
Tags: Blood Culture, Sepsis
Date Published: April 27, 2015
Source article link: Momentum BioScience » company contact details
Bruker Introduces Novel PCR Assays for Aspergillosis and Carbapenem Resistance
FDA Clearance for BacT/ALERT® VIRTUO™ Fully Automated Blood Culture System
bioMérieux Your Expert in Infectious Diseases at ECCMID 2017
FDA Clears Auto Susceptibility Test Directly from Positive Blood Cultures
Baker Ruskinn Launches New Anaerobic and Microaerophilic Workstations